Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

Annals of the Rheumatic Diseases

Volumn 74, Issue 4, 2015, Pages 694-702

  McInnes, Iain B ^a   Thompson, Liz ^b   Giles, Jon T ^c   Bathon, Joan M ^c   Salmon, Jane E ^d   Beaulieu, Andre D ^e   Codding, Christine E ^f   Carlson, Timothy H ^g   Delles, Christian ^a   Lee, Janet S ^h   Sattar, Naveed ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c Howard Hughes Medical Institute   (United States)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

^e LAVAL UNIVERSITY   (Canada)

^f Health Research of Oklahoma   (United States)

^g Pacific Biomarkers   (United States)

^h HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; CORTICOSTEROID; D DIMER; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6 RECEPTOR; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PROTEIN SPLA2 IIA; SECRETORY PHOSPHOLIPASE A2; TOCILIZUMAB; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; IL6R PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PHOSPHOLIPASE A2 GROUP II; SERUM AMYLOID A;

ADULT; ARTICLE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RHEUMATOID ARTHRITIS; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DYSLIPIDEMIA; ECHOGRAPHY; METABOLISM;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; GROUP II PHOSPHOLIPASES A2; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PULSE WAVE ANALYSIS; RECEPTORS, INTERLEUKIN-6; SERUM AMYLOID A PROTEIN; TRIGLYCERIDES;

EID: 84925670384     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204345     Document Type: Article

References (31)

1. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-31.
2. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 125-32.
3. McKellar GE, McCarey DW, Sattar N, et al. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol 2009; 6: 410-17.
4. Sattar N, McCarey DW, Capell H, et al. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63.
5. Hurt-Camejo E, Paredes S, Masana L, et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: Possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 2001; 44: 2761-67.
6. Chung CP, Oeser A, Raggi P, et al. Lipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis. J Rheumatol 2010; 37: 1633-8.
7. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: A challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68: 460-9.
8. Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol 2006; 17: 412-17.
9. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. J Lipid Res 2004; 45: 1169-96.
10. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518-28.
11. Wannamethee SG, Whincup PH, Shaper AG, et al. Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men. J Thromb Haemost 2009; 7: 1605-11.
12. Kishimoto T. IL-6: From its discovery to clinical applications. Int Immunol 2010; 22: 347-52.
13. Sattar N, Murray HM, Welsh P, et al. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?. PLoS Med 2009; 6: E1000099.
14. Danesh J, Kaptoge S, Mann AG, et al. Long-Term interleukin-6 levels and subsequent risk of coronary heart disease: Two new prospective studies and a systematic review. PLoS Med 2008; 5: E78.
15. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-25.
16. Interleukin 6 Receptor Mendelian Randomisation Analysis (IL6R MR) ConsortiumHingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: A Mendelian randomisation analysis. Lancet 2012; 379: 1214-24.
17. IL6R Genetics Consortium Emerging Risk Factors CollaborationSarwar N, Butterworth AS, et al. Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-Analysis of 82 studies. Lancet 2012; 379: 1205-13.
18. Mäki-Petäjä KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-Tumor necrosis factor-Alpha therapy. Circulation 2006; 114: 1185-92.
19. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: Methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-605.
20. Patel AM, Moreland LW. Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy. Drug Design Dev Ther 2010; 4: 263-78.
21. Kume K, Amano K, Yamada S, et al. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: An open-label randomized controlled trial. J Rheumatol 2011; 38: 2169-71.
22. van Eijk IC, de Vries MK, Levels JH, et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009; 60: 1324-30.
23. Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23: 1881-8.
24. Hashizume M, Yoshida H, Koike N, et al. Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. Ann Rheum Dis 2010; 69: 741-6.
25. Gierens H, Nauck M, Roth M, et al. Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements. Arterioscler Thromb Vasc Biol 2000; 20: 1777-83.
26. Hashizume M, Mihara M. Atherogenic effects of TNF-A and IL-6 via up-regulation of scavenger receptors. Cytokine 2012; 58: 424-30.
27. Carpentier YA, Scruel O. Changes in the concentration and composition of plasma lipoproteins during the acute phase response. Curr Opin Clin Nutr Metab Care 2002; 5: 153-8.
28. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly: The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19: 493-8.
29. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease: Prospective study and meta-Analysis. Circulation 2001; 103: 2323-7.
30. Emerging Risk Factors CollaborationErqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-23.
31. Sattar N, Crompton P, Cherry L, et al. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study. Arthritis Rheum 2007; 56: 831-9.